Phio Pharmaceuticals Announced That The Safety Monitoring Committee Recommended Dose Escalation In Its Phase 1B Trial To Evaluate The Safety And Tolerability Of PH-762 For Stages 1, 2, And 4 Cutaneous Squamous Cell Carcinoma, Stage 4 Melanoma, And...

Phio Pharmaceuticals公告安全監測委員會建議在其10億階段試驗中提高劑量，以評估PH-762在1、2和4期鱗狀細胞癌、4期黑色素瘤和...

Benzinga · 2024/12/19 20:50

Phio Pharmaceuticals Announced That The Safety Monitoring Committee Recommended Dose Escalation In Its Phase 1B Trial To Evaluate The Safety And Tolerability Of PH-762 For Stages 1, 2, And 4 Cutaneous Squamous Cell Carcinoma, Stage 4 Melanoma, And Stage 4 Merkel Cell Carcinoma

Phio Pharmaceuticals宣佈安全監測委員會推薦在其10億階段試驗中增加劑量，以評估PH-762在1、2和4期皮膚鱗狀細胞癌、4期黑色素瘤和4期梅克爾細胞癌中的安全性和耐受性。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。